On September 24, Twist Bioscience Corp rose 5.16% in regular trading, trading at $166.29/share with turnover of $28.22 million, staging a strong rebound following the prior session's pullback.
On the news front, the company recently announced a collaboration with Lilly TuneLab, Eli Lilly's AI/ML drug discovery platform, to provide antibody characterization data services supporting AI-driven drugability prediction and validation workflows. Notably, Twist's AI drug discovery-related orders have doubled from $25 million to $50 million, with projections to reach $100 million the following year. As the AI pharmaceutical arms race intensifies, Twist continues to capture market attention as a critical link in the AI design-to-wet lab verification loop.
Adding further momentum, in August, Twist was selected by Anthropic as an independent evaluator for a multi-arm AI protein design project, which drove shares up over 17% at the time. On the fundamentals side, Twist reported fiscal Q3 revenue of $118.4 million, beating the $114.5 million estimate, and guided Q4 revenue to $123-124 million versus the $117.4 million consensus. UBS recently initiated coverage with a Neutral rating and a $144 price target.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments